Approach to Patients with Suspected Fungal Infections


CD4+ T lymphocyte cell count (cells/µl)

Fungal infections

> 500

Candidal vaginitis

200–500

Thrush (oropharyngeal candidiasis)

< 200

PCP, disseminated histoplasmosis, disseminated coccidioidomycosis

< 100

Cryptococcosis, candidal esophagitis, penicilliosis


PCP Pneumocystis pneumonia





Organ Transplantation


Solid organ and HSCT recipients are at great risk for fungal infections [1618]. In addition to immunosuppressive therapies, the mucosal damage and intensive therapy associated with these procedures place the persons who receive them at risk for the entire spectrum of fungal disease. Transplant medicine has seen substantial advancements in tailoring regimens to minimize the duration of neutropenia and to reduce immunosuppressive treatments used to control rejection. Unfortunately, most of these still place patients at a substantial risk for opportunistic infections. In solid organ transplantation, the risk of fungal infection is associated with risk surrounding the initial surgery and the use of immunosuppression to prevent rejection. This risk varies greatly based on organ transplanted and underlying condition of the recipient. As an example, in liver transplantation, the substantial risk of Candida infection in the first month is mostly associated with surgical manipulation of the gastrointestinal tract and the need for intensive care monitoring, as well as initial immunosuppressive agents given to control rejection (Table 1.2). Lung transplants are at high risk for invasive pulmonary aspergillosis, likely secondary to the route of inoculation and immunosuppression. Although a similar sequence of occurrence of fungal infection is seen in HSCT, the underlying factors creating risk differ from those of solid organ transplant (Table 1.3). In HSCT, initial conditioning commonly leads to neutropenia and breakdown of the mucosal surfaces. This neutropenia can be prolonged and associated with life-threatening mold infections. In allogeneic HSCT, graft-versus-host disease (GvHD) and its treatment may put the patient at risk for fungal infection for a prolonged period of time following engraftment.


Table 1.2
Fungi associated with hematopoietic stem cell transplantation
























Time period

Common fungi

Other fungi

Preengraftment (< 30 days)

Candida

Aspergillus

Postengraphment (30–100 days)

Aspergillus, Candida, Pneumocystis

Mucorales, Fusarium, Pseudallescheria (Scedosporium)

Late (> 100 days)

Aspergillus, Pneumocystis
 



Table 1.3
Fungi associated with solid organ transplantation. (Table produced from data in reference [16])
























Time period

Common fungi

Other fungi

First month

Candida
 

1–6 months

Aspergillus, Pneumocystis, Cryptococcus

Endemic fungia

> 6 months

Endemic fungia

Cryptococcus


aChiefly, coccidioides and histoplasma



Health Care Exposure (Nosocomial)


A multitude of risk factors for nosocomial fungal infections have been identified (Table 1.4) [6, 19, 20]. Unfortunately, many of these health care-associated risk factors overlap with those associated with bacterial infections or are risks that are common to many or most hospitalized patients. This is especially true for those patients hospitalized in intensive care units, the majority of whom have central venous catheters and are receiving broad-spectrum antibiotics [21, 22]. In addition to the use of vascular catheters, other procedures including urinary catheterization and intubation establish portals of entry for fungal pathogens. Other risk factors include immunosuppression seen with the use of corticosteroids and chemotherapy, and with malnutrition and malignancy. Infusion of contaminated infusates, inclusion of lipids in parenteral nutrition, and construction within the hospital are additional exposures that can lead to fungal infections. A few specific risks allow the clinician to suspect certain fungi. Ketoacidosis and deferoxamine therapy has been clearly shown to be a risk for mucormycosis (zygomycosis). Unfortunately, given the overlapping nature of most of these risk factors with those associated with bacterial infections, it is often difficult to apply these risk factors to differentiate patients at higher risk of fungal versus bacterial infection.


Table 1.4
Risk factors commonly associated with health care-associated invasive mycoses (Table produced from data in reference [17])
















Mycosis

Risk factors

Candidiasis

Candida colonization, surgery (especially abdominal), acute renal failure, parenteral nutrition, central venous catheters, neutropenia, broad-spectrum antibacterial antimicrobials, mucosal surface disruption

Aspergillosis

Prolonged neutropenia, corticosteroids, neutrophil dysfunction, hematologic malignancy, cytotoxic drugs, AIDS, HSCT (highest in allogeneic), solid organ transplantation (highest heart-lung), underlying lung disease, GvHD, GvHD therapies (TNF-α blockers)


HSCT hematopoietic stem cell transplantation, GvHD graft-versus-host disease, TNF-α tumor necrosis factor alpha


Community Exposure


The fungi that cause community-acquired infections commonly originate in the environment and are “true pathogens” (i.e., cause disease in persons with normal immune status). Most are restricted to certain geographic environments or exposure risks (Table 1.5). The source of disease includes inhalation, ingestion, or traumatic inoculation of the fungi. Diseases most commonly afflict the lungs, paranasal sinuses, skin, and soft tissues. Rarely, disseminated, central nervous system, or osteoarticular disease occurs. The most commonly recognized community-acquired infections are the endemic mycoses, each with their limited geographical areas of exposure. With the extensive use of antibiotics, corticosteroids, and other immune modulators in the community, as well as the increased number of elderly, and population of immunocompromised persons receiving their care outside of the hospital, the boundaries between community-acquired and health care-associated infection have become blurred.


Table 1.5
Geographic areas in which the endemic mycoses reside






































Mycosis

Region

Specific countries/areas with increased prevalence

Associated exposure risksa

Blastomycosis

North Americab

Southeastern and South central USA, Canada

Soil exposure near fresh water (fishing, hunting, farming, construction)

Coccidioidomycosis

Western hemisphere

Southwestern USA, Central and South America

Soil/dust exposure (construction, archeology)

Histoplasmosis

Worldwide

Mississippi and Ohio River valleys, Western Africa

Soil or organic material associated with bird or bat guano (construction, demolition, spelunking)

Paracoccidioidomycosis

Latin America

Brazil, Columbia, Venezuela, Ecuador, Argentina

Farming or other outdoor employment

Penicilliosisc

Southeast Asia

China, Northeast India, Taiwan, Thailand, Vietnam

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 1, 2017 | Posted by in INFECTIOUS DISEASE | Comments Off on Approach to Patients with Suspected Fungal Infections

Full access? Get Clinical Tree

Get Clinical Tree app for offline access